Agoracom Blog

Candente Copper $DNT.ca Adopts Shareholder Rights Plan $CN.ca $FCX $BHP $TECK.ca

Posted by AGORACOM at 8:07 AM on Tuesday, August 11th, 2020

VANCOUVER, British Columbia, Aug. 11, 2020 (GLOBE NEWSWIRE) — Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper” or the “Company”) advises that Mr. Luis Miguel Inchaustegui Zevallos has resigned as Advisor and Director of our Peruvian subsidiary, Cañariaco Copper Perú S.A. (”Cañariaco”) and has been named Minister of Energy and Mines of Peru. 

We thank Mr. Inchaustegui for all of his excellent advice and wish him all the best in his new endeavours.

On another matter the Company also advises that the Board of Directors has adopted a new shareholder rights plan (“Rights Plan”), which is designed to encourage the fair treatment of the Company’s Shareholders in connection with any potential take‑over bid for the Company. The Rights Plan is not intended to deter or prevent take‑over bids and is similar to plans adopted recently by several other Canadian public companies and approved by their Shareholders. 

Background and Purpose of the Rights Plan

The Rights Plan will:

  1. encourage the fair treatment of shareholders of the Company in connection with any Offer to Acquire the outstanding Voting Shares;
  2. ensure, to the extent possible, that the shareholders of the Company and the Board of Directors have adequate time to consider and evaluate any unsolicited Offer to Acquire the outstanding Voting Shares;
  3. ensure, to the extent possible, that the Board of Directors has adequate time to identify, develop and negotiate value-enhancing alternatives, as appropriate, to any unsolicited Offer to Acquire the outstanding Voting Shares; and
  4. generally assist the Board of Directors to enhance shareholder value.

Take‑over bid contests for corporate control provide a singular opportunity for Shareholders to obtain a one‑time gain. After the acquisition of effective control, the opportunity for this one‑time gain normally does not re‑occur. As with most public companies, it is possible for a person to secure control of the Company through the ownership of much less than 50% of the Company’s shares. Without a shareholder rights plan, a bidder could acquire effective control of the Company over a relatively short period of time, through open market and private purchases and using various techniques permitted under Canadian securities legislation, all without making a bid available to all Shareholders. This acquisition of control would probably be an effective deterrent to other potential offerors. The person acquiring control might also be able to consolidate and increase its control, over a period of time, without the price for control ever being tested through an open market auction. Shareholder rights plans are designed to prevent this occurrence by forcing all acquisitions of control into a public offer mode.

A public offer will not necessarily achieve all of the objectives of ensuring the maximum value to Shareholders. The Rights Plan is intended to provide the Board with sufficient time to pursue alternatives and to provide Shareholders with sufficient time to properly assess any take‑over bid.

The Company is not proposing the Rights Plan in response to or in anticipation of any acquisition or take‑over bid. The Rights Plan is not intended to prevent a take‑over of the Company, to secure continuance of current management or the directors in office, or to deter fair offers for the Company’s shares. The Rights Plan does not inhibit or prevent any Shareholder from using the proxy mechanism set out in the BCBCA to promote a change in the management or direction of the Company. The Rights Plan may, however, increase the price to be paid by a potential offeror to obtain control of the Company and may discourage certain transactions.

The Rights Plan does not affect in any way the Company’s financial condition. The initial issuance of the Rights will not dilute the Company’s shares and will not affect reported earnings or cash flow per share until the Rights separate from the underlying common shares and become exercisable. The adoption of the Rights Plan will not lessen or affect the duty of the Company’s directors to act honestly, in good faith, and in the Company’s best interests. The Rights Plan is designed to provide the directors with the means to negotiate with an offeror and with sufficient time to seek out and identify alternative transactions on behalf of the Shareholders.

The Rights Plan is subject to Toronto Stock Exchange and Shareholder approval at the upcoming Annual General Meeting on September 17th, 2020.  If the Shareholders do not approve the Rights Plan, it will terminate or not become effective, as applicable. The Rights Plan will also expire if the Rights are redeemed by the Company. A copy of the Rights Plan Agreement can be requested for review to [email protected].Once the Rights Plan has been approved, it will be filed on SEDAR at www.sedar.com and posted on the Company’s website at www.candentecopper.com.

About Candente Copper
Candente Copper is a mineral exploration company engaged in acquisition, exploration, and development of mineral properties. The Company is currently focused on its 100% owned Cañariaco project, which includes the Feasibility stage Cañariaco Norte deposit as well as the Cañariaco Sur deposit and Quebrada Verde prospect, located within the western Cordillera of the Peruvian Andes in the Department of Lambayeque in Northern Peru.

At Cañariaco Norte, 7.5 billion pounds of copper have been delineated in a Measured and Indicated* resource of 752.4 million tonnes grading 0.49% copper equivalent** and an Inferred Resource of 157.7 million tonnes at 0.44% copper equivalent has also been delineated.

Fifteen drill holes have confirmed that Cañariaco Sur hosts a porphyry-copper deposit, however the average grade and full dimensions of the deposit are as yet unknown. Quebrada Verde also hosts a geochemical and geophysical target where porphyry style copper mineralization is exposed in creek beds. 

Candente Copper also holds other porphyry copper-gold exploration projects in Peru. 

Joanne C. Freeze, P.Geo., CEO, is the Qualified Person as defined by National Instrument 43-101 for the projects discussed above. She has reviewed and approved the contents of this release.

*The ‘Measured and Indicated Resource listed above consists of Measured Resources of 338.1Mt at 0.48% Cu , 0.08 g/t Au, and 2.0/t Ag (0.52% Cu Eq.), plus Indicated Resources of 414.3Mt at 0.43% Cu, 0.06 g/t Au, and 1.8 g/t Ag (o.46% Cu Eq.).  All resources quoted in this release are based on a 0.30% copper cut-off grade and 229 drill holes completed to the end of 2008.

**Copper equivalent grade including gold and silver, metal recoveries (copper 90%, gold 55%; silver 50%) and smelter returns (copper 96.5%: gold 93%; silver 90%) applied. Copper grade equivalent calculation: Cu Eq% =(Cu % + ((Au grade x Au price x Au recovery x Au smelter return%)+(Ag grade x Ag price x Ag recovery x Ag smelter return%))/(22.0462 x Cu price x 31.0135 g/t x Cu recovery x Cu smelter return%). The metal prices used are: copper US$2.50/lb, gold US$1,035/oz and silver US$17.25/oz.

On behalf of the Board of Candente Copper Corp.

“Joanne C. Freeze” P.Geo.
President, CEO and Director
___________________________________
For further information please contact:

“Joanne C. Freeze” P.Geo.
President, CEO and Director
Tel +1 604-689-1957
[email protected]
www.candentecopper.com

Avicanna $AVCN.ca and Red White & Bloom Enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived #CBD-Based Topical Products in the United States $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 8:06 AM on Tuesday, August 11th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Entered into a distribution agreement for the exclusive distribution of Avicanna’s advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by RWB in the US and certain other markets.
  • The partnership allows for both companies to stake a claim in the expanding $532 billion beauty industry with the most advanced and only clinically backed CBD skin care line

TORONTO, Aug. 11, 2020 – Avicanna Inc. (“Avicanna”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, and Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) (“RWB” or “Red White & Bloom”) are pleased to announce that they have entered into a distribution agreement for the exclusive distribution of Avicanna’s advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by RWB in the US and certain other markets.

The $532 billion beauty industry continues growing rapidly and new trends such as the introduction of CBD cosmetics is anticipated to establish a strong market presence in markets that permit retail sales such as the United States. The Pura H&W branded products utilize hemp-derived CBD, the non-psychoactive and non-controlled cannabinoid, which allows for cosmetic designation and retail sales.

The launch of this innovative and premium hemp-derived CBD product line will leverage from the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform, third party e-commerce channels, and “big box” retailers in addition to the existing commercial infrastructure of RWB in the United States.

Brad Rogers, chairman and chief executive officer of RWB, stated: “Throughout my career, I have seen tremendous success licensing brands, strategically leveraging them for the demographics that recognize the best in class quality & efficacy, and then listing them in big box and specialty retailers. This agreement paves a path that will allow RWB and Avicanna to grow together well into the future beyond our news today.”

Under the agreement, which has an initial five-year term, RWB will exclusively distribute the Pura H&W™ brand and certain other white label brands at RWB’s direction. Having been developed by researchers and collaborators from world class medical and academic institutions, the Pura H&W™ line of products has been developed through a scientific and evidence-based approach. This approach in product development has allowed Avicanna to synergistically combine natural ingredients with hemp-derived CBD in advanced and proprietary formulations that have completed 3 cosmetic human clinical studies. Product development is always commenced with the consumer in mind and specific needs are addressed through analysis in observational as well as interventional clinical studies. Avicanna’s hemp-derived CBD infused cosmetics and topicals equip RWB with the opportunity to set the standards with advanced research and development for hemp-derived CBD cosmetics and GMP manufacturing.

The 3 cosmetic clinical studies were completed on Avicanna’s formulations targeted at cosmetic factors associated with aging, acne-prone skin, and eczema-prone skin. The successfully completed studies involved 156 patients that were tested for both safety and certain derma-cosmetic endpoints, including hydration and excess oil production. The results of all three studies achieved positive results in the endpoints with no adverse effects, making products part of one of the only cannabinoid consumer product lines with human safety and efficacy data.

Aras Azadian, CEO of Avicanna, commented: “After years of R&D and clinical development of what we believe is the most advanced line of CBD skin care products, we are thrilled to have partnered up with the team at RWB, who provide an ideal partner for Avicanna and the Pura H&W line of products. We believe their access and expertise in the US market through commercial and retail channels will allow the Pura H&W branded products to reach their potential as the leading skin care brand.”

Terms of the agreement

RWB will pay Avicanna an upfront licensing fee in the amount of two hundred fifty thousand Canadian dollars (CAD$250,000) in cash, along with minimum purchase requirements for the rights to be the exclusive distributor of Avicanna’s Pura H&W branded cosmetic products in the US. Under the agreement, RWB also has the right to purchase Avicanna’s cosmetic products for distribution into the US and certain other territories under brands of RWB’s choosing. The initial product offerings under the agreement will include body and face lotions, cosmetic creams, gels and serums, as well as soaps and bath bombs.

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Red White & Bloom Brands Inc.

The Company is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominately focusing its investments on the major US markets, including Michigan, Illinois, Massachusetts, California, and Florida with respect to cannabis, and the US and internationally for hemp-based CBD products.

For more information about Red White & Bloom Brands Inc., please contact:

Tyler Troup, Managing Director

Circadian Group IR

[email protected]

Visit us on the web: www.RedWhiteBloom.com

Follow us on social media:

Twitter: @rwbbrands

Facebook: @redwhitebloombrands

Instagram: @redwhitebloombrands

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of Avicanna or RWB to perform under the agreement, the manufacturing of the products, the shipping and delivery of the products to customers in the United States and worldwide, and the appropriate education and marketing efforts. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Else Nutrition $BABY.ca Announces North American Launch of World’s Only Real Alternative to Dairy-Based Baby Nutrition $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:22 AM on Tuesday, August 11th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Baby Nutrition Paradigm shift: After 120 years, Else introduces a completely novel protein source for baby nutrition (over one year old) with a breakthrough, clean and sustainable production process.
  • Globally patented, and founded by infant nutrition industry veterans, Else Nutrition is the first dairy and soy- free, clean label, plant-based complete nutrition for babies (1 year and over).
  • A Revolution in the way babies are fed, Else Nutrition offers parents a great- tasting, dairy-free, soy-free and GMO-free alternative.
  • Else Plant-Based Complete Nutrition is now available for purchase at elsenutrition.com, U.S. shipping nationwide and to Canada.

VANCOUVER, BC / August 11, 2020 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY) (OTCQX:BABYF) (FSE:0YL) (“Else” or the “Company“), today announces the online product launch of its Else Plant-Based Complete Toddler Nutrition, the first fully certified USDA Organic, Clean Label, Plant-Based, Soy-Free nutritional drink for toddlers. Made with ingredients, vitamins and minerals that help support growth and development after a baby’s first year. Else Plant-Based Complete Nutrition is the only globally-patented, real alternative for babies beyond the first year – including those with milk intolerances/sensitivities, those looking to avoid dairy and soy, and for all families looking for a clean, plant-based option for their children

Dairy-free, soy-free, corn syrup-free, gluten-free and non-GMO, Else Nutrition is a unique globally patented combination of whole-plant organic ingredients – almonds buckwheat and tapioca. This combination meets the gold standard equivalent of human milk nutritional composition values, based on WHO international standards, among others. Else Plant- Nutrition meets the strictest regulatory requirements and the highest nutrition standards, providing a full essential amino acid profile and a clean source of protein. It is manufactured in an infant grade U.S. manufacturing site and endorsed by a board of leading U.S. and international pediatricians and nutritionists.

“We are thrilled that today marks a huge leap forward in plant-based alternatives in the baby and toddler category,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “For more than 120 years, cow’s milk and soy have dominated. After seven years of R&D, we are finally able to offer something else to parents and bring a real, clean label alternative to families across North America, so that they will never have to compromise on the health and nutrition of their toddler again.”

Else Plant-Based Complete Nutrition for Toddlers is minimally processed. Else intends for all its future products to meet this standard. With more than seven years of research and development, Else’s breakthrough process creates nutrition products from whole plants without altering their chemistry or using highly-processed extracts, or harsh chemicals. Through this disruptive process, Else is able to maximize the nutritional value and minimize environmental impact.

Additionally, Else Nutrition’s innovation pipeline includes a breakthrough, plant-based, clean label infant formula for babies 0-12 months. It is anticipated to launch in approximately two years, currently on its pathway for final FDA approval.

Beyond the brand’s Advisory Board of Pediatricians and nutritionists, Else has already captured the attention of many influential mothers, such as Hilaria Baldwin. As a mother of four with the fifth on the way, Hilaria came across Else as she searched for nutrition products for her toddler Romeo. After using the product, Hilaria decided to partner with Else to support its product launch.

Else Plant-Based Complete Nutrition for Toddlers is now available at elsenutrition.com, currently priced at $36 for a single 22 oz. powder canister and $136 for a 4-pack. The product will also be offered on Amazon.com later this month and in select retail chains sometime during Q4 2020.

Disruptive,Beyond Organic’ Production Process

Else products are minimally processed, using the cleanest production process in the infant nutrition industry. Else’s ‘Beyond Organic’ disruptive manufacturing process transforms whole plants to tasty toddler nutrition, without using highly-processed extracts or derivatives, harsh chemicals, or high-fructose corn syrup. Changing only the texture of the plants, and never the fundamental chemistry, allowing for more of the nutrients that nature intended to nourish the child.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

Media Contact:

Covet Consumer Business Unit
Gianna Totaro
[email protected]
P: 1-301-875-6574

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will,” “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Empower $CBDT.ca #Covid19 Testing Growth Adds to Revenue Diversification with Record July 2020 Patient Visits and Record Revenue Per Patient $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:18 AM on Tuesday, August 11th, 2020
  • Empower July 2020 patient volume surpasses 2,300 patients with Sun Valley Health increasing revenue per patient by 29%,
  • Adds 426 COVID-19 patient tests in July 2020 pilot testing program

VANCOUVER, BC / AUGUST 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company continues to execute on its plan to diversify revenue sources with 2,317 patient visits in July 2020 with record revenues coming from medical cannabis certifications, naturopathic consultations, product sales, identification card production and COVID-19 testing services.

“Diversification of revenue sources utilizing the strength of our clinic, physician, technology and operational assets has been a mission of ours.” said Steven McAuley, Chairman & CEO of Empower. “To see our team, deliver record performance in such a challenging environment, validates our execution strategy, validates the daily commitment of our team members and demonstrates we are on the right path to delivering significant shareholder value.”

The Arizona Department of Health Services announced yesterday its Phased Reopening Plan for Paused Industries indicating that community spread remains: Substantial based on the status of three main criteria: 1) Cases per 100,000 individuals: Substantial, 2) Percent positivity: Substantial, and 3) Hospital visits for COVID-like illnesses in the region: Substantial.

A dashboard available at azhealth.gov/businessCOVID19 indicates whether counties meet the recommended benchmarks for reopening of gyms, movie theaters, waterparks, tubing venues, and bars.

Further information is available at:

https://www.azdhs.gov/director/public-information-office/index.php#news-release-081020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company conducts COVID-19 testing in its clinics under a four-phase national launch in the United States.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Hollister Biosciences $HOLL.ca Closes $1.5 Million Private Placement Financing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:11 PM on Monday, August 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced non-brokered private placement financing by issuance of 17,646,889 units at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000

VANCOUVER, BC, Aug. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, is pleased to announce that it has closed its previously announced non-brokered private placement financing by issuance of 17,646,889 units (the “Units” and each individually, a “Unit“) at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000 (the “Offering“).  

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant. Each warrant will be exercisable into Share at a price of $0.10 until August 10, 2022.

The Company has paid eligible finders cash commission in the total amount of $108,201.26. The Company has also issued non-transferable compensation options (“Finder’s Options“) to finders to acquire up to a total of 1,272,959 Units (“Finder’s Units“), at a price of $0.085 per Finder’s Unit on or before August 10, 2022. Each Finder’s Unit will consist of one Share and one non-transferable share purchase warrant (the “Finder’s Warrant“). Each Finder’s Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share on or before August 10, 2022.

All securities issued in connection with the Offering are subject to a statutory hold period of four-months and one day ending on December 11, 2020. The Company intends to use the net proceeds of the Offering for the expansion of Venom Extracts, Hollister’s 100% owned subsidiary, into California and for working capital and general corporate purposes.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities issued in connection with the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

VIDEO: Vegaste Technologies $VEGA.ca Closes 1st Day Of Trading With $75,000,000 Market Cap & Revenue Run Rate Of $US 3,000,000

Posted by AGORACOM-JC at 8:02 PM on Monday, August 10th, 2020
PlantX | LinkedIn

AGORACOM prides itself on becoming the discovery platform of emerging disruptive companies …. and we’ve discovered another one today in Vegaste Technologies, an e-commerce driven platform that is delivering all things plant-based to customers across Canada right now.    

Vegaste has already started with both plant-based food meals directly to homes, thanks to partnerships right across the country – but isn’t stopping there as it adds hundreds of products to the platform.  More than just lip service, Vegaste is already on a $US 3,000,000 run rate and that will probably accelerate in the coming months as marketing and additional products kick in.  

Vegaste Founder, Sean Dollinger, is no stranger to AGORACOM followers as he was the Co-Founder behind wildly successful Namaste Technologies before it fell on hard times experienced by the cannabis industry.  In addition to bringing back his immense e-commerce capabilities, he’s also implemented some valuable lessons learned at Namaste when it comes to corporate governance and share structure.  

One of those lessons was appointing Julia Frank as CEO and giving her the team necessary to focus on doing the best job possible.  Julia’s experience combines both start-up and big corporation structures thanks to being part of start-up teams within both BMW and Daimler in Germany.    

Vegaste is hot off the listing press, so if you ever wanted to get a jump on your fellow investor it doesn’t get much fresher than this ….. unless you’re ordering a plant based meal off their platform at www.PlantX.com

If you believe in the paradigm shifting nature of plant based foods, be sure to watch and share this great interview with Vegaste CEO Julia Frank CEO & Founder Sean Dollinger.

Loop $MTRX.ca Announces Two Webinars For Investor Community $QUIS.ca $MCLD.ca $NXO.ca

Posted by AGORACOM-JC at 3:35 PM on Monday, August 10th, 2020
Loop Insights – Medium

  • Announced two webinars taking place on August 11th and 20th
  • Viewers can log on to RBMG’s live webinar at 4:30PM ET on Aug 11 (1:30PM PT)
  • Viewers can log on to SmallCap Power’s live webinar at 11:00AM ET on Aug 20th (8AM PT)

VANCOUVER, BC, Aug. 10, 2020  – Loop Insights Inc. (TSXV: MTRX) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated contact tracing to the brick and mortar space, announced two webinars taking place on August 11th and 20th through two esteemed investing firm platforms, SmallCap Power and RB Milestone Group (“RBMG”).

HOW TO REGISTER

Loop CEO Rob Anson will be providing an investor update on Loop’s current operations, its upcoming milestones, and how the Company is leveraging its technology for contactless, automated contact tracing to assist brick and mortar businesses reopen their doors in an expedited and safe manner during the pandemic

Viewers can log on to RBMGs live webinar at 4:30PM ET on Aug 11 (1:30PM PT).

Register here: https://attendee.gotowebinar.com/register/3783698096339223820. To ask a question, you will need to be logged into the GoToWebinar platform or by emailing your question(s) beforehand to [email protected]. The Webinar will be recorded and posted to Loop’s website following the presentation.

Viewers can log on to SmallCap Powers live webinar at 11:00AM ET on Aug 20th (8AM PT).

Register here: https://register.gotowebinar.com/register/568728291875965698.

A STRATEGIC MOVE TO INCREASE THE COMPANYS VISIBILITY EXPONENTIALLY

The Company will leverage the two firms’ large investor audiences to widen its visibility and diversify its investment portfolio. SmallCap Power is known to highlight young, innovative companies that have significant growth potential and offers an addressable investor audience of 3 million. RBMG offers Loop a proprietary database comprised of over 10,000 institutional investors, HNWs, UHNWs, family offices, brokers and research analysts throughout the US, setting the stage for Loop’s in-progress listing on the OTCQB® American Venture Market.

CEO Rob Anson explained: There’s no greater time to become acquainted with Loop’s story and fully understand the scope of this investing opportunity. The company is gaining huge market traction. In July we traded more stocks than we have in this past year while being on the public market; and on July 17th, we saw a 100% increase in stock price. We are catching fire, and we want this to be known among the global investor community.”

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&A https://agoracom.com/ir/LoopInsights/forums/discussion

About SmallCapPower: SmallCapPower is the industry’s leading and most trusted source for small-cap stock coverage, research, and analysis. Our investment philosophy is predicated on discovering smaller, underfollowed, and under researched public companies, which have significant growth potential.

About RBMG: Our US advisory practice delivers investor relations programs tailor-made for emerging companies who are private and publicly traded on the NYSE, NASDAQ, OTC, TSX, TSXV, CSE, ASX and AIM. It helps companies refine their communications strategies, weigh data, and advise clients on how to penetrate new markets.

About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.

Forward-Looking Statements/Information: 

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

SOURCE LOOP Insights Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2020/10/c9908.html

Loop Insights Inc., Investing Relations, T: +1 877-754-5336 Ext. 4, E: [email protected]; CHF Capital Markets, Cathy Hume, CEO, T: 416-868-1079 x 231, E: [email protected]; LOOP Website: www.loopinsights.ai, Facebook: @LoopInsights, Twitter: @LoopInsights , LinkedIn: @LoopInsightsCopyright CNW Group 2020

The Real Promise of LSD, MDMA and Mushrooms for Medical Science SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM at 11:47 AM on Monday, August 10th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

  • Psychedelic science is making a comeback.

Scientific publications, therapeutic breakthroughs and cultural endorsements suggest that the historical reputation of psychedelics — such as lysergic acid diethylamide (LSD), mescaline (from the peyote cactus) and psilocybin (mushrooms) — as dangerous or inherently risky have unfairly overshadowed a more optimistic interpretation. Recent publications, like Michael Pollan’s How to Change your Mind, showcase the creative and potentially therapeutic benefits that psychedelics have to offer — for mental health challenges like depression and addiction, in palliative care settings and for personal development. 

Erika Dyck

Major scientific journals have published articles showing evidence-based reasons for supporting research in psychedelic studies. These include evidence that pscilocybin significantly reduces anxiety in patients with life-threatening illnesses like cancer, that MDMA (3,4-methylenedioxy-methamphetaminecan; also known as ecstasy) improves outcomes for people suffering from PTSD and that psychedelics can produce sustained feelings of openness that are both therapeutic and personally enriching

Other researchers are investigating the traditional uses of plant medicines, such as ayahuasca, and exploring the neurological and psychotherapeutic benefits of combining Indigenous knowledge with modern medicine.

I am a medical historian, exploring why we now think that psychedelics may have a valuable role to play in human psychology, and why over 50 years ago, during the heyday of psychedelic research, we rejected that hypothesis. What has changed? What did we miss before? Is this merely a flashback?

Healing trauma, anxiety, depression

In 1957, the word psychedelic officially entered the English lexicon, introduced by British-trained and Canadian-based psychiatrist Humphry Osmond

Osmond studied mescaline from the peyote cactus, synthesized by German scientists in the 1930s, and LSD, a laboratory-produced substance created by Albert Hofmann at Sandoz in Switzerland. During the 1950s and into the 1960s, more than 1,000 scientific articles appeared as researchers around the world interrogated the potential of these psychedelics for healing addictions and trauma.

But, by the end of the 1960s, most legitimate psychedelic research ground to a halt. Some of the research had been deemed unethical, namely mind-control experiments conducted under the auspices of the CIA. Other researchers had been discredited for either unethical or self-aggrandizing use of psychedelics, or both.

Timothy Leary was perhaps the most notorious character in that regard. Having been dismissed from Harvard University, he launched a recreational career as a self-appointed apostle of psychedelic living. 
Drug regulators struggled to balance a desire for scientific research with a growing appetite for recreational use, and some argued abuse, of psychedelics.

In the popular media, these drugs came to symbolize hedonism and violence. In the United States, the government sponsored films aimed at scaring viewers about the long-term and even deadly consequences of taking LSD. Scientists were hard-pressed to maintain their credibility as popular attitudes began to shift.

Now that interpretation is beginning to change.

https://news.usask.ca/articles/research/2018/the-real-promise-of-lsd,-mdma-and-mushrooms-for-medical-science.php

Gold-Silver Ratio Reaches Its Highest Level In 87 Years From Its Lowest Level In 41 Years SPONSOR: Affinity Metals $AFF.ca $MKR.ca $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca $RKR.ca

Posted by AGORACOM at 9:56 AM on Monday, August 10th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564657/hub/Affinity_Metals_Corp_Logo.png

Affinity is focused on the acquisition, exploration and development of strategic metal deposits within North America. In addition to the West Timmins Gold project, Affinity is advancing the Regal Project in the northern end of the prolific Kootenay Arch. Regal hosts two major geophysical anomalies as well as three past producing mines. Recent drill results included a new silver discovery with an 11.10 meter interval of 143.29 g/t silver which included a 0.55 meter interval of 2,612.0 g/t silver Click Here For More Info

  • The gold-silver ratio indicates how many ounces of silver are required to buy one ounce of gold. In time periods where the ratio is relatively high, it acts as a leading indicator for a rise in silver’s value

As technical indicators go, the ratio of gold price to silver prices, commonly referred to as the gold-silver ratio, is considered by precious metal traders to be one of the most reliable indicators for forward price movements in silver.

The gold-silver ratio indicates how many ounces of silver are required to buy one ounce of gold. In time periods where the ratio is relatively high, it acts as a leading indicator for a rise in silver’s value.

Previously the highest the ratio has ever been was 132 to 1 in 1933, when the US government invoked Executive Order 6102 and forced US citizens to sell all but a small portion of their gold and silver holdings to the Federal Reserve.

In more recently the highest the ratio has reached id 97.3 to 1 in February 1991 (Figure 1), at the height of a global economic recession. After this high in the ratio, the silver price rose in a continued uptrend from an average price of US$3.74/oz in February 1991 to US$6.84/oz in February 1998, an increase of 83%.

Figure 1: Gold-Silver Ratio since 1990

Source: Mining and Metals Research Corporation Ltd.

In June 2003, after a sustained five-year period of lower gold-silver ratios, the gold-silver ratio reached a high of 78.7:1, over the next five years the silver price rose from US$4.53/oz to a high of US$19.32/oz in March 2008, (Figure 1) an increase of 326%.

A spike in the gold-silver ratio in December 2008 to 79.3:1, associated with another global recession, was a leading indicator of a 315% increase in the silver price from US$10.29/oz in December 2008 to US$42.7 in April 2011 (Figure 1).

The gold-silver ratio has now risen from a low of 34.7:1 in April 2011, its lowest level since 1979, to its highest level in 87 years of 111.7:1 in April 2020, before reducing to 90.6:1 in July on the back of a 35% rise in the silver price over just three months (Figure 1).

Could we now be facing a sustained uptrend in the silver price?

Historical precedent appears to suggests so, only once in history was silver more undervalued compared to gold than it was in April 2020 and that was in 1933 when the US Government forced its citizens to sell their precious metal holdings.

Source: https://www.proactiveinvestors.co.uk/companies/news/926237/gold-silver-ratio-reaches-its-highest-level-in-87-years-from-its-lowest-level-in-41-years-926237.html

Kontrol’s $KNR.ca COVID-19 Technology Receives Initial Positive Lab Test Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 9:24 AM on Monday, August 10th, 2020
kontrol-logo

— Kontrol BioCloud® —

  • Announced that the detection mechanism of the Kontrol BioCloud® analyzer, has received initial positive lab results
  • Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments
  • The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time
  • This part of the ongoing testing is anticipated to be completed in the next two to three weeks

TORONTO, ON / August 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the detection mechanism of the Kontrol BioCloud® analyzer (“BioCloud“), has received initial positive lab results.

Can we measure for COVID-19 like we do for air quality?

Drawing from its extensive industry experience in air emissions and air quality monitoring, Kontrol is developing a new technology designed to detect and alert for COVID-19 in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments.

“We are pleased to announce that our detection mechanism, previously announced on August 5th, 2020, has completed its initial proof of concept test results. We have now validated that our detection mechanism can detect COVID-19 specific components in air samples under a controlled experiment,” says Paul Ghezzi, Chief Executive Officer of Kontrol. “The controlled testing was conducted by independent consultants, Dr. David Heinrichs, PhD (Heinrichs Laboratory), and Dr. Jimmy Dikeakos, PhD (Dikeakos Laboratory) – experts in the study of Microbiology and Immunology.”

Next Stage of Testing

The initial testing was designed to validate the function of the detection mechanism. The testing was limited to a controlled environment with the detection mechanism, and not the complete operation of the BioCloud analyzer.

The next stage of testing will be with the live COVID-19 virus in a controlled environment and the BioCloud prototype operating in real-time. This part of the ongoing testing is anticipated to be completed in the next two to three weeks. It is important to note that Kontrol is not making any representations about the operation of the BioCloud analyzer at this time. Following the testing of the BioCloud analyzer in real-time the lab results will be announced, and a final report will be prepared for the National Research Council of Canada for their review.

“As we continue testing, we have also started the process of establishing procurement and supply chain solutions for the potential production of the BioCloud and we remain in discussions with the National Research Council of Canada for their continued support,” says Gary Saunders, VP of Kontrol. “Given the urgency of creating safe spaces as the economy re-opens, we are working around the clock to move our technology forward and we appreciate the efforts of our team.”

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.


Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.